InterVene, Inc. raised $13M in a Series A led by Treo Ventures and RiverVest Venture Partners to advance the Recana™ system through US market clearance.

Oct 07, 2024•about 1 year ago

Amount Raised

$13 Million

Round Type

series a

Redwood CityHealthcare

Investors

River Vest Venture PartnersTreo Ventures

Description

InterVene, Inc. announced the closing of its $13M Series A financing round co-led by Treo Ventures and RiverVest Venture Partners. The proceeds will fund the final development of its Recana catheter system and support preparation for initial commercialization.

Company Information

Company

InterVene

Location

Redwood City, California, United States

About

InterVene is a medical device start-up company reinventing the way physicians treat severe venous disease in the legs. InterVene's BlueLeaf(TM) Endovenous Valve Formation System represents the first ever non-implantable, endovenous approach to deep vein valve failure. This technology allows physicians to create new vein valves for patients who are unable to efficiently pump blood out of their legs and back to their heart. Millions of Americans currently suffer from painful venous stasis ulcers (VSU’s) and other costly and devastating symptoms, yet no minimally invasive therapy exists to treat deep vein valve failure, one of the most prevalent underlying causes of these symptoms. InterVene plans to change that.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends